jRCT2071260028尚未招募不适用
A Phase I/IIa Investigator-Initiated Clinical Trial to Evaluate the Safety and Efficacy of Sivelestat in Patients with Acute Relapse of Neuromyelitis Optica Spectrum Disorder (SIVAR-NMOSD trial)
未提供0 个研究点目标入组 7 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Patients diagnosed with anti-AQP4 antibody-positive NMOSD according to the international diagnostic criteria for NMOSD (Wingerchuk, Neurology 2015).
- •2.Patients experiencing a relapse including any of the following, with the relapse occurring within 14 days of obtaining consent:
- •i. Unilateral or bilateral optic neuritis
- •ii. Myelitis
- •Patients whose FS domain has worsened by at least 1 point due to relapse.
- •Patients with one or more relapse lesions identified on MRI (however, if the relapse is considered to have occurred in the same location as an existing MRI lesion neurologically, identification of a new relapse lesion is not required).
- •Patients aged 18 years or older at the time of obtaining consent.
- •Female patients of childbearing potential who agree to use appropriate contraception from the time of obtaining consent until 180 days after the end of investigational product administration.
- •7.Male patients who agree to use appropriate contraception until 90 days after the end of investigational product administration.
- •Patients who can provide written informed consent.
排除标准
- •Patients with multi-organ dysfunction involving 4 or more organs.
- •Patients with severe chronic respiratory disease.
- •Patients with autoimmune diseases other than NMOSD that are expected to require additional treatment during the study period.
- •Patients with active systemic bacterial, viral, or fungal infections.
- •Patients who have received either or both of the following prior treatments after an NMOSD relapse:
- •i. Two or more courses of steroid pulse therapy
- •ii. Plasmapheresis
- •iii. High-dose immunoglobulin therapy
- •Patients with severe hepatic dysfunction.
- •Patients with alcohol dependence, drug dependence, or psychiatric disorders that would interfere with study participation.
- •Patients who have received other investigational drugs within 3 months prior to obtaining consent.
- •Pregnant women, women suspected of being pregnant, or breastfeeding women.
- •Patients with allergies to the investigational product or concomitant medications.
- •Patients with severe allergies or a history of severe allergies.
- •Patients with suicidal tendencies meeting any of the following criteria:
- •i. Within 1 month prior to the screening assessment, there was suicidal behavior or ideation corresponding to "Yes" for Item 4 (Active suicidal ideation -some intent to act, but no specific plan) or Item 5 (Active suicidal ideation -specific plan and intent) of the Columbia-Suicide Severity Rating Scale (C-SSRS). (For subjects who only met Items 1-3, inclusion may be permitted at the discretion of the principal investigator or sub-investigator.)
- •ii. Any suicidal behavior based on Item 6 of the C-SSRS occurred within the past 3 months.
- •Other patients judged inappropriate by the principal investigator or sub-investigator.
研究者
相似试验
招募中
不适用
A Phase II Investigator-Initiated Clinical Trial Evaluating the Efficacy and Safety of Combination Therapy with a PAI-1 Inhibitor (TM5614) and Immune Checkpoint Inhibitor Consolidation Therapy following Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (TM-Alliance study) (TM-Alliance study)non-small cell lung cancerjRCT206126000127
招募中
不适用
A multicenter, Investigator-initiated Clinical Trial Comparing a Novel BRT therapy With Standard Therapy in Patients with Anti-MDA5-Antibody-Positive dermatomyositis who have multiple poor prognostic factorsPatients with MDA5-DM-ILD who have multiple poor prognostic factorsjRCT206126000944
招募中
不适用
Investigator-Initiated Phase II Clinical Trial of MA-5 for Mitochondrial Disease
An Exploratory, Investigator-Initiated Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MA-5 in Patients with Mitochondrial Disease and Hearing LossMitochondrial disease with hearing lossjRCT203125050515
尚未招募
不适用
Safety Evaluation Study of Pitavastatin PLGA nano-particle for Retinitis Pigmentosa (RP CLARITI trial)Retinitis PigmentosajRCT207126000621
尚未招募
2 期
A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaNCT07379424chen chao Professor37